PT Mobile Logo

Search form


Panic Disorder and Pregnancy: Challenges of Caring for Mother and Child

Panic Disorder and Pregnancy: Challenges of Caring for Mother and Child

Panic disorder (PD) is a common psychiatric illness that can have a chronic, relapsing course. Epidemiological data has documented a lifetime prevalence of 0.4% to 3.5%, and the illness usually begins during early to middle adulthood with a female to male preponderance (Weissman et al., 1997). Other data have shown that after remission of panic symptoms, women may be more likely than men to experience recurrence of panic attacks (Yonkers et al., 1998).

The question of whether pregnancy represents a time of increased risk for recurrence of panic symptoms has been a matter of debate. Several authors have suggested that pregnancy may provide a protective effect in the course of panic disorder. For example, George et al. (1987) reported a small case series of three women with PD who showed marked improvement in their panic symptoms during pregnancy. Villeponteaux et al. (1992) conducted a small retrospective study on pregnant women with pre-existing PD and reported that a majority of women had an improvement in panic symptoms during pregnancy. Altshuler et al. (1998) found that whereas pregnancy appears to exacerbate symptoms of obsessive compulsive disorder, patients with PD may remain well during pregnancy even after discontinuing medication. In contrast to the above findings, Cohen et al. (1996) conducted a small prospective study on the course of pre-existing PD during pregnancy and found that most patients continued to experience panic attacks during all three trimesters and required anti-panic medication.

Our group has conducted a seven-year, naturalistic follow-up study in order to examine the effect of pregnancy on the course of pre-existing panic disorder. Our results demonstrated that pregnancy may confer an increased risk of relapse in PD. Moreover, when compared to patients who develop PD while not pregnant, patients who have the initial onset of PD during pregnancy appear to have a higher risk of relapse at the time of a subsequent pregnancy (Dannon, unpublished data).

While the effect of pregnancy seems to have a variable influence on the course of PD, multiple studies have demonstrated that the postpartum period appears to be associated with an increased risk of relapse (Cohen et al., 1996; Northcott and Stein, 1994; Sholomskas et al., 1993; Wenzel et al., 2005). It should be noted that Wisner et al. (1996) conducted a historical, prospective study of women with panic disorder (n=22) and found no change in the course of panic symptoms postnatally, as compared to the pre-pregnancy baseline. On the other hand, one interesting observation from this study was that first lifetime onset of PD was common postpartum.

While it is well accepted that PD has disabling effects in terms of social and occupational functioning, there is also evidence that untreated anxiety in pregnant women may adversely affect the developing fetus. In a cohort of 100 pregnant women with a mean gestation of 32 weeks, Teixeira et al. (1999) found a significant association between uterine artery resistance and maternal scores for state and trait anxiety. Another finding was the strong correlation between plasma levels in the mother and in the fetus, leading the investigators to postulate that elevated maternal cortisol may have a direct effect on the development of the fetal brain (Glover, 1999). In support of this theory, it has been suggested that the hypothalamic-pituitary-adrenocortical (HPA) system (elevated cortisol levels) or sympathetic activation may have contributed to the findings of increased uterine artery resistance in anxious mothers (Field et al., 2003).

The approach to treating the pregnant woman with symptomatic PD must take into consideration the potential risks to the fetus of pharmacotherapeutic intervention versus the possible risks of untreated maternal anxiety. Benzodiazepines are widely prescribed for the treatment of panic disorder, but their use should generally be avoided in women who are pregnant or who wish to conceive. Benzodiazepines used in the first trimester have been associated with a small but increased risk of oral cleft and congenital malformations of the central nervous system and the urinary tract (Altshuler et al., 1996). Maternal use of benzodiazepines in the perinatal period has also been shown to produce neonatal withdrawal symptoms and may cause respiratory depression and muscular hypotonia in the neonate.

Selective serotonin reuptake inhibitors are highly effective anti-panic agents and are commonly used in treating young women with PD (Ballenger et al., 1998). Several prospective studies of SSRIs have shown no increase in the incidence of miscarriage or major malformations associated with their use (Kulin et al., 1998; Wisner et al., 1999). The SSRIs, however, have U.S. Food and Drug Administration use-in-pregnancy ratings of either B or C, indicating that the risks and benefits of treatment must be considered on a case-by-case basis, and treatment options must be discussed carefully with the patient. Among the SSRIs, fluoxetine (Prozac) has been the best studied in terms of reproductive safety while information regarding the use of sertraline (Zoloft), paroxetine (Paxil), fluvoxamine (Luvox) and citalopram (Celexa) during pregnancy is limited, due to small sample size (Nonacs and Cohen, 2003). A prospective study of the serotonergic noradrenergic reuptake inhibitor (SNRI) venlafaxine (Effexor) during the first trimester of pregnancy showed no increase in the risk of major malformations as compared with non-exposed controls (Einarson et al., 2001). It should be kept in mind that the use of paroxetine prior to delivery has been associated with a high rate of neonatal complications such as respiratory distress and hypoglycemia (Costei et al., 2002).


Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.